Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.

MLA

Triplett, Todd A., et al. “Reversal of Indoleamine 2,3-Dioxygenase-Mediated Cancer Immune Suppression by Systemic Kynurenine Depletion with a Therapeutic Enzyme.” Nature Biotechnology, vol. 36, no. 8, Sept. 2018, pp. 758–64. EBSCOhost, https://doi.org/10.1038/nbt.4180.

APA

Triplett, T. A., Garrison, K. C., Marshall, N., Donkor, M., Blazeck, J., Lamb, C., Qerqez, A., Dekker, J. D., Tanno, Y., Lu, W.-C., Karamitros, C. S., Ford, K., Tan, B., Zhang, X. M., McGovern, K., Coma, S., Kumada, Y., Yamany, M. S., Sentandreu, E., … Georgiou, G. (2018). Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme. Nature Biotechnology, 36(8), 758–764. https://doi.org/10.1038/nbt.4180

Chicago

Triplett, Todd A, Kendra C Garrison, Nicholas Marshall, Moses Donkor, John Blazeck, Candice Lamb, Ahlam Qerqez, et al. 2018. “Reversal of Indoleamine 2,3-Dioxygenase-Mediated Cancer Immune Suppression by Systemic Kynurenine Depletion with a Therapeutic Enzyme.” Nature Biotechnology 36 (8): 758–64. doi:10.1038/nbt.4180.